Abstract
A series of p38 mitogen-activated protein kinase (MAPK) inhibitors based upon an 8-benzoylimidazo[1,2-a]pyridin-5-one scaffold are claimed. Their use for the treatment of inflammatory disease, especially chronic obstructive pulmonary disease, is also claimed. This represents a relatively unusual use of MAPK inhibitors. The scaffold employed represents a novel variant on the arylazole scaffold commonly employed in designing MAPK inhibitors.